Free Newsletter
Roche warns of Tamiflu psych effects
After some arm-twisting from the FDA, Roche has added stronger warnings to its Tamiflu label. In a Dear Healthcare Professional letter, the company cautioned doctors about the sometimes-fatal psychiatric problems seen in a small number of patients. Some have gone delirious and hurt themselves, even killed themselves, by falling from windows or balconies or running into traffic.
An FDA advisory committee discussed the problems at a November meeting, where the agency revealed nearly 600 reports of psychiatric troubles in Tamiflu patients, three-fourths of them in Japan. But because the flu itself can cause delirium and hallucinations, the new Tamiflu label states that the drug hasn't been definitively linked to the behavior problems.
Now, Australian regulators say they're keeping an eye on Tamiflu. They've updated the labeling for the drug, too.
- read the story in Forbes
- check out the Australian reaction in The Age
Related Articles:
Tamiflu resistant to seasonal strains. Report
FDA does a triple-take on Tamiflu. Report
Tamiflu's Japanese sales to drop by half. Report
Roche's Tamiflu ads spark criticism. Report
EU approves Tamiflu for children. Report
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline


SHARE
WITH: